Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer

Seema Agarwal, Frank B. Gertler, Michele Balsamo, John S. Condeelis, Robert L. Camp, Xiaonan (Nan) Xue, Juan Lin, Thomas E. Rohan, David L. Rimm

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction: Mena, an Ena/VASP protein family member, is a key actin regulatory protein. Mena is up-regulated in breast cancers and promotes invasion and motility of tumor cells. Mena has multiple splice variants, including Mena invasive (MenaINV) and Mena11a, which are expressed in invasive or non-invasive tumor cells, respectively. We developed a multiplex quantitative immunofluorescence (MQIF) approach to assess the fraction of Mena lacking 11a sequence as a method to infer the presence of invasive tumor cells represented as total Mena minus Mena11a (called Menacalc) and determined its association with metastasis in breast cancer.Methods: The MQIF method was applied to two independent primary breast cancer cohorts (Cohort 1 with 501 and Cohort 2 with 296 patients) using antibodies against Mena and its isoform, Mena11a. Menacalc was determined for each patient and assessed for association with risk of disease-specific death.Results: Total Mena or Mena11a isoform expression failed to show any statistically significant association with outcome in either cohort. However, assessment of Menacalc showed that relatively high levels of this biomarker is associated with poor outcome in two independent breast cancer cohorts (log rank P = 0.0004 for Cohort 1 and 0.0321 for Cohort 2). Multivariate analysis on combined cohorts revealed that high Menacalc is associated with poor outcome, independent of age, node status, receptor status and tumor size.Conclusions: High Menacalc levels identify a subgroup of breast cancer patients with poor disease-specific survival, suggesting that Menacalc may serve as a biomarker for metastasis.

Original languageEnglish (US)
Article numberR124
JournalBreast Cancer Research
Volume14
Issue number5
DOIs
StatePublished - Sep 12 2012

Fingerprint

Protein Isoforms
Breast Neoplasms
Fluorescent Antibody Technique
Neoplasms
Biomarkers
Neoplasm Metastasis
Cell Movement
Actins
Multivariate Analysis
Survival
Antibodies
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. / Agarwal, Seema; Gertler, Frank B.; Balsamo, Michele; Condeelis, John S.; Camp, Robert L.; Xue, Xiaonan (Nan); Lin, Juan; Rohan, Thomas E.; Rimm, David L.

In: Breast Cancer Research, Vol. 14, No. 5, R124, 12.09.2012.

Research output: Contribution to journalArticle

@article{9472b1e67c5a4491879daf0c158597d0,
title = "Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer",
abstract = "Introduction: Mena, an Ena/VASP protein family member, is a key actin regulatory protein. Mena is up-regulated in breast cancers and promotes invasion and motility of tumor cells. Mena has multiple splice variants, including Mena invasive (MenaINV) and Mena11a, which are expressed in invasive or non-invasive tumor cells, respectively. We developed a multiplex quantitative immunofluorescence (MQIF) approach to assess the fraction of Mena lacking 11a sequence as a method to infer the presence of invasive tumor cells represented as total Mena minus Mena11a (called Menacalc) and determined its association with metastasis in breast cancer.Methods: The MQIF method was applied to two independent primary breast cancer cohorts (Cohort 1 with 501 and Cohort 2 with 296 patients) using antibodies against Mena and its isoform, Mena11a. Menacalc was determined for each patient and assessed for association with risk of disease-specific death.Results: Total Mena or Mena11a isoform expression failed to show any statistically significant association with outcome in either cohort. However, assessment of Menacalc showed that relatively high levels of this biomarker is associated with poor outcome in two independent breast cancer cohorts (log rank P = 0.0004 for Cohort 1 and 0.0321 for Cohort 2). Multivariate analysis on combined cohorts revealed that high Menacalc is associated with poor outcome, independent of age, node status, receptor status and tumor size.Conclusions: High Menacalc levels identify a subgroup of breast cancer patients with poor disease-specific survival, suggesting that Menacalc may serve as a biomarker for metastasis.",
author = "Seema Agarwal and Gertler, {Frank B.} and Michele Balsamo and Condeelis, {John S.} and Camp, {Robert L.} and Xue, {Xiaonan (Nan)} and Juan Lin and Rohan, {Thomas E.} and Rimm, {David L.}",
year = "2012",
month = "9",
day = "12",
doi = "10.1186/bcr3318",
language = "English (US)",
volume = "14",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "5",

}

TY - JOUR

T1 - Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer

AU - Agarwal, Seema

AU - Gertler, Frank B.

AU - Balsamo, Michele

AU - Condeelis, John S.

AU - Camp, Robert L.

AU - Xue, Xiaonan (Nan)

AU - Lin, Juan

AU - Rohan, Thomas E.

AU - Rimm, David L.

PY - 2012/9/12

Y1 - 2012/9/12

N2 - Introduction: Mena, an Ena/VASP protein family member, is a key actin regulatory protein. Mena is up-regulated in breast cancers and promotes invasion and motility of tumor cells. Mena has multiple splice variants, including Mena invasive (MenaINV) and Mena11a, which are expressed in invasive or non-invasive tumor cells, respectively. We developed a multiplex quantitative immunofluorescence (MQIF) approach to assess the fraction of Mena lacking 11a sequence as a method to infer the presence of invasive tumor cells represented as total Mena minus Mena11a (called Menacalc) and determined its association with metastasis in breast cancer.Methods: The MQIF method was applied to two independent primary breast cancer cohorts (Cohort 1 with 501 and Cohort 2 with 296 patients) using antibodies against Mena and its isoform, Mena11a. Menacalc was determined for each patient and assessed for association with risk of disease-specific death.Results: Total Mena or Mena11a isoform expression failed to show any statistically significant association with outcome in either cohort. However, assessment of Menacalc showed that relatively high levels of this biomarker is associated with poor outcome in two independent breast cancer cohorts (log rank P = 0.0004 for Cohort 1 and 0.0321 for Cohort 2). Multivariate analysis on combined cohorts revealed that high Menacalc is associated with poor outcome, independent of age, node status, receptor status and tumor size.Conclusions: High Menacalc levels identify a subgroup of breast cancer patients with poor disease-specific survival, suggesting that Menacalc may serve as a biomarker for metastasis.

AB - Introduction: Mena, an Ena/VASP protein family member, is a key actin regulatory protein. Mena is up-regulated in breast cancers and promotes invasion and motility of tumor cells. Mena has multiple splice variants, including Mena invasive (MenaINV) and Mena11a, which are expressed in invasive or non-invasive tumor cells, respectively. We developed a multiplex quantitative immunofluorescence (MQIF) approach to assess the fraction of Mena lacking 11a sequence as a method to infer the presence of invasive tumor cells represented as total Mena minus Mena11a (called Menacalc) and determined its association with metastasis in breast cancer.Methods: The MQIF method was applied to two independent primary breast cancer cohorts (Cohort 1 with 501 and Cohort 2 with 296 patients) using antibodies against Mena and its isoform, Mena11a. Menacalc was determined for each patient and assessed for association with risk of disease-specific death.Results: Total Mena or Mena11a isoform expression failed to show any statistically significant association with outcome in either cohort. However, assessment of Menacalc showed that relatively high levels of this biomarker is associated with poor outcome in two independent breast cancer cohorts (log rank P = 0.0004 for Cohort 1 and 0.0321 for Cohort 2). Multivariate analysis on combined cohorts revealed that high Menacalc is associated with poor outcome, independent of age, node status, receptor status and tumor size.Conclusions: High Menacalc levels identify a subgroup of breast cancer patients with poor disease-specific survival, suggesting that Menacalc may serve as a biomarker for metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84866041637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866041637&partnerID=8YFLogxK

U2 - 10.1186/bcr3318

DO - 10.1186/bcr3318

M3 - Article

VL - 14

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 5

M1 - R124

ER -